NCT04377711View on ClinicalTrials.gov

A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

June 8, 2020

Primary Completion Date

January 5, 2021

Study Completion Date

January 5, 2021

Conditions
COVID-19
Interventions
DRUG

Ciclesonide

160mcg Inhaler

DRUG

Placebo

Matching Placebo Inhaler

Trial Locations (1)

14203

University of Buffalo, Buffalo

Sponsors
All Listed Sponsors
lead

Covis Pharma S.à.r.l.

INDUSTRY

NCT04377711 - A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients | Biotech Hunter | Biotech Hunter